[go: up one dir, main page]

AU2003251271A1 - USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES - Google Patents

USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES

Info

Publication number
AU2003251271A1
AU2003251271A1 AU2003251271A AU2003251271A AU2003251271A1 AU 2003251271 A1 AU2003251271 A1 AU 2003251271A1 AU 2003251271 A AU2003251271 A AU 2003251271A AU 2003251271 A AU2003251271 A AU 2003251271A AU 2003251271 A1 AU2003251271 A1 AU 2003251271A1
Authority
AU
Australia
Prior art keywords
driven
basophil
treatment
mast cell
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003251271A
Inventor
Per-Olof Ericsson
Karin Kristensson
Paschalis Sideras
Peter Sjo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2003251271A1 publication Critical patent/AU2003251271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003251271A 2002-08-14 2003-08-13 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES Abandoned AU2003251271A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202464A SE0202464D0 (en) 2002-08-14 2002-08-14 Use of compounds
SE0202464-4 2002-08-14
PCT/SE2003/001274 WO2004016270A1 (en) 2002-08-14 2003-08-13 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES

Publications (1)

Publication Number Publication Date
AU2003251271A1 true AU2003251271A1 (en) 2004-03-03

Family

ID=20288752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003251271A Abandoned AU2003251271A1 (en) 2002-08-14 2003-08-13 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES

Country Status (3)

Country Link
AU (1) AU2003251271A1 (en)
SE (1) SE0202464D0 (en)
WO (1) WO2004016270A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146585A1 (en) * 2004-04-20 2008-06-19 Ab Science Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103804381A (en) * 2012-11-06 2014-05-21 韩冰 Compound for treatment of ischemic brain damage and application thereof
CN107567445B (en) 2015-02-02 2021-06-29 坎塞拉有限公司 2-Phenyl-3H-imidazo[4,5-B]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ROR1 activity
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
ES2899113T3 (en) 2016-07-11 2022-03-10 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivatives useful as inhibitors of mammalian ROR1 tyrosine kinase activity
EP4263538A1 (en) * 2020-12-15 2023-10-25 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL340727A1 (en) * 1997-11-10 2001-02-26 Bristol Myers Squibb Co Benzothiazolic inhibitors of proteinous thyrosinic kinase
ES2306671T3 (en) * 1999-10-07 2008-11-16 Amgen Inc. TRIAZINE QUINASA INHIBITORS.
KR100755622B1 (en) * 1999-12-24 2007-09-04 아벤티스 파마 리미티드 Azaindol
CA2433018A1 (en) * 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases

Also Published As

Publication number Publication date
WO2004016270A1 (en) 2004-02-26
SE0202464D0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2003255413A1 (en) Use of lck inhibitor for treatment of immunologic diseases
PT1487828E (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
AU2003295336A1 (en) Use of etodoclac to treat hyperplasia
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
AU2003260778A1 (en) Treatment of pipes
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
IL162818A0 (en) Combination therapy for the treatment of bacterialinfections
AU2003251271A1 (en) USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2003259074A1 (en) Gal3 antagonists for the treatment of neuropathic pain
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
AU2003270615A1 (en) Treatment of steatosis using hyperthermia
GB2410744B (en) Kinase inhibitors for the treatment of disease
GB0201025D0 (en) The treatment of degenerative diseases
AU2003252185A1 (en) Topical composition for the treatment of scar tissue

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase